F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome before and after anti-CD20 antibody rituximab therapy

Wei Jen Shih; Nasrin Ghesani; Zhuang Hongming; Abass Alavi; Steven Schusper; Davis Mozley

doi:10.1097/00003072-200202000-00019

F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome before and after anti-CD20 antibody rituximab therapy

Wei Jen Shih, Nasrin Ghesani, Zhuang Hongming, Abass Alavi, Steven Schusper, Davis Mozley

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Salivary gland non-Hogdgkin's lymphoma (NHL) in patients with Sjogren's syndrome frequently develops from rheumatoid factor B cells. The authors describe a patient with NHL of the parotid glands associated with Sjogren's syndrome whose initial positron emission tomographic (PET) findings included abnormal F-18 fluorodeoxyglucose (FDG) uptake in the parotid glands. After rituximab therapy, a follow-up PET study confirmed a positive response to treatment. This illustrates that F-18 FDG PET can be used to monitor the therapeutic response of NHL parotid glands associated with Sjogren's syndrome.

Original language	English (US)
Pages (from-to)	142-143
Number of pages	2
Journal	Clinical nuclear medicine
Volume	27
Issue number	2
DOIs	https://doi.org/10.1097/00003072-200202000-00019
State	Published - 2002

All Science Journal Classification (ASJC) codes

Radiology Nuclear Medicine and imaging

Keywords

Fluorine-18 Fluorodeoxyglucose
Monoclonal Antibody Therapy
Non-Hodgkin's Lymphoma
Rituximab
Sjogren's Syndrome

Access to Document

10.1097/00003072-200202000-00019

Cite this

Shih, W. J., Ghesani, N., Hongming, Z., Alavi, A., Schusper, S., & Mozley, D. (2002). F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome before and after anti-CD20 antibody rituximab therapy. Clinical nuclear medicine, 27(2), 142-143. https://doi.org/10.1097/00003072-200202000-00019

@article{05212a11cb4e4cf6a333a6405d4a8541,

title = "F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome before and after anti-CD20 antibody rituximab therapy",

abstract = "Salivary gland non-Hogdgkin's lymphoma (NHL) in patients with Sjogren's syndrome frequently develops from rheumatoid factor B cells. The authors describe a patient with NHL of the parotid glands associated with Sjogren's syndrome whose initial positron emission tomographic (PET) findings included abnormal F-18 fluorodeoxyglucose (FDG) uptake in the parotid glands. After rituximab therapy, a follow-up PET study confirmed a positive response to treatment. This illustrates that F-18 FDG PET can be used to monitor the therapeutic response of NHL parotid glands associated with Sjogren's syndrome.",

keywords = "Fluorine-18 Fluorodeoxyglucose, Monoclonal Antibody Therapy, Non-Hodgkin's Lymphoma, Rituximab, Sjogren's Syndrome",

author = "Shih, {Wei Jen} and Nasrin Ghesani and Zhuang Hongming and Abass Alavi and Steven Schusper and Davis Mozley",

year = "2002",

doi = "10.1097/00003072-200202000-00019",

language = "English (US)",

volume = "27",

pages = "142--143",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "2",

}

Shih, WJ, Ghesani, N, Hongming, Z, Alavi, A, Schusper, S & Mozley, D 2002, 'F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome before and after anti-CD20 antibody rituximab therapy', Clinical nuclear medicine, vol. 27, no. 2, pp. 142-143. https://doi.org/10.1097/00003072-200202000-00019

F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome before and after anti-CD20 antibody rituximab therapy. / Shih, Wei Jen; Ghesani, Nasrin; Hongming, Zhuang et al.
In: Clinical nuclear medicine, Vol. 27, No. 2, 2002, p. 142-143.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome before and after anti-CD20 antibody rituximab therapy

AU - Shih, Wei Jen

AU - Ghesani, Nasrin

AU - Hongming, Zhuang

AU - Alavi, Abass

AU - Schusper, Steven

AU - Mozley, Davis

PY - 2002

Y1 - 2002

N2 - Salivary gland non-Hogdgkin's lymphoma (NHL) in patients with Sjogren's syndrome frequently develops from rheumatoid factor B cells. The authors describe a patient with NHL of the parotid glands associated with Sjogren's syndrome whose initial positron emission tomographic (PET) findings included abnormal F-18 fluorodeoxyglucose (FDG) uptake in the parotid glands. After rituximab therapy, a follow-up PET study confirmed a positive response to treatment. This illustrates that F-18 FDG PET can be used to monitor the therapeutic response of NHL parotid glands associated with Sjogren's syndrome.

AB - Salivary gland non-Hogdgkin's lymphoma (NHL) in patients with Sjogren's syndrome frequently develops from rheumatoid factor B cells. The authors describe a patient with NHL of the parotid glands associated with Sjogren's syndrome whose initial positron emission tomographic (PET) findings included abnormal F-18 fluorodeoxyglucose (FDG) uptake in the parotid glands. After rituximab therapy, a follow-up PET study confirmed a positive response to treatment. This illustrates that F-18 FDG PET can be used to monitor the therapeutic response of NHL parotid glands associated with Sjogren's syndrome.

KW - Fluorine-18 Fluorodeoxyglucose

KW - Monoclonal Antibody Therapy

KW - Non-Hodgkin's Lymphoma

KW - Rituximab

KW - Sjogren's Syndrome

UR - http://www.scopus.com/inward/record.url?scp=0036147619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036147619&partnerID=8YFLogxK

U2 - 10.1097/00003072-200202000-00019

DO - 10.1097/00003072-200202000-00019

M3 - Article

C2 - 11786752

AN - SCOPUS:0036147619

SN - 0363-9762

VL - 27

SP - 142

EP - 143

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 2

ER -

F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome before and after anti-CD20 antibody rituximab therapy

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this